A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome-Reference-Cited by-同舟云学术

A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome

Published:2024-03-27 Issue:7 Volume:59 Page:1025-1027
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Koo Ray Mun,Wong Eric,Davis Joanne E.,Perera Travis,Lim Andrew,Koldej Rachel M.^ORCID,Ritchie David S.^ORCID

Funder

The Snowdome Foundation. Celgene Corporation, a Bristol-Myers Squibb Company.

Leukaemia Foundation

Haematology Society of Australia and New Zealand

The Snowdome Foundation. Celgene Corporation, a Bristol-Myers Squibb Company. Fight Cancer Foundation Fay Duncan Women in Research Fellowship

Maddie Riewoldt’s Vision Fellowship (MRV-0030). The Snowdome Foundation. Celgene Corporation, a Bristol-Myers Squibb Company.

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41409-023-02195-x.pdf

Reference12 articles.

1. Bejanyan N, Weisdorf DJ, Logan BR, Wang HL, Devine SM, de Lima M, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2015;21:454–9.

2. Ciurea SO, Labopin M, Socie G, Volin L, Passweg J, Chevallier P, et al. Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center. Cancer. 2018;124:2134–41.

3. Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 2012;119:1599–606.

4. Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience. Am J Hematol. 2018;93:1074–81.

5. Orti G, Barba P, Fox L, Salamero O, Bosch F, Valcarcel D. Donor lymphocyte infusions in AML and MDS: enhancing the graft-versus-leukemia effect. Exp Hematol. 2017;48:1–11.